Chemotherapy for breast cancer often bring the side effect of early menopause to women, yet a new research shows some guarded promise for preventing early menopause patients with breast cancer. The outcomes are published in the Journal of the American Medical Association.
While most breast cancer is determined at later ages, about 6% of women learn that they're ill before 40 years old - when they're still of childbearing age. Treatments of Breast cancer that have shown the finest results for for disease free survival include chemotherapy, hormonal therapy, or both of them. As younger women still hope for children, these treatments can cause disastrous short-term or long-term loss of menstrual periods, and losing fertility. Although many women choose to preserve the option of having children by storing eggs before cancer treatment, the process can be costly and difficult.
Italian researchers performed a phase three research that included 281 breast cancer women, aged 18 to 45 years and who had not experienced menopause. Patients were randomly selected to be dealt with chemotherapy alone or with chemotherapy and triptorelin, a drug, called a GnRH analogue, that prevents the ovaries from releasing eggs. The researchers followed the women for one year after they had finished chemotherapy.
In the women who had not received triptorelin, early menopause rate was 25.9%. While in the women who had received triptorelin, early menoapuse rate was 8.9%, which is 17% lower.
An associated editorial by Dr. Hope S. Rugo and Dr. Mitchell P. Rosen of the University of California-San Francisco says that trptorelin therapy shouldn't be recommended as a standard treatment and should be approached with caution in women who had hormone-sensitive disease. They also stress that women resuming their menstrual cycles does not mean the same thing as women preserving their fertility. They conclude that using assisted reproductive technology - such as storing eggs before chemotherapy, is "the most effectiveoption for fertility preservation."
While most breast cancer is determined at later ages, about 6% of women learn that they're ill before 40 years old - when they're still of childbearing age. Treatments of Breast cancer that have shown the finest results for for disease free survival include chemotherapy, hormonal therapy, or both of them. As younger women still hope for children, these treatments can cause disastrous short-term or long-term loss of menstrual periods, and losing fertility. Although many women choose to preserve the option of having children by storing eggs before cancer treatment, the process can be costly and difficult.
Italian researchers performed a phase three research that included 281 breast cancer women, aged 18 to 45 years and who had not experienced menopause. Patients were randomly selected to be dealt with chemotherapy alone or with chemotherapy and triptorelin, a drug, called a GnRH analogue, that prevents the ovaries from releasing eggs. The researchers followed the women for one year after they had finished chemotherapy.
In the women who had not received triptorelin, early menopause rate was 25.9%. While in the women who had received triptorelin, early menoapuse rate was 8.9%, which is 17% lower.
An associated editorial by Dr. Hope S. Rugo and Dr. Mitchell P. Rosen of the University of California-San Francisco says that trptorelin therapy shouldn't be recommended as a standard treatment and should be approached with caution in women who had hormone-sensitive disease. They also stress that women resuming their menstrual cycles does not mean the same thing as women preserving their fertility. They conclude that using assisted reproductive technology - such as storing eggs before chemotherapy, is "the most effectiveoption for fertility preservation."
0 comments:
Post a Comment